Locatie:<\/strong> Hilton at UAB Downtown<\/p>\nVrijdag 1 mei 2026<\/strong>
\nMedisch symposium: <\/strong>8u00-17u00
\nLocatie:<\/strong> Marnix E. Heersink Conference Center aan de University of Alabama at Birmingham
\nMedische receptie medisch symposium: <\/strong>18u00-20u00
\nLocatie:<\/strong> Marnix E. Heersink Conference Center aan de University of Alabama at Birmingham<\/p>\nZaterdag 2 mei 2026<\/strong>
\nVergadering ECD-zorgcentrum: <\/strong>8u00-11u00
\nLocatie:<\/strong> UAB Cancer Center<\/p>\nDit evenement brengt de wereldwijde gemeenschap van Erdheim-Chester samen met vooraanstaande medische experts om het laatste onderzoek, klinische inzichten en hulpmiddelen voor de gemeenschap te delen. Deelnemers kunnen educatieve sessies verwachten, gelegenheden om in contact te komen met collega’s en updates over nieuwe behandelingen en pati\u00ebntenzorg.<\/p>\n
Meer details over het hotel en de hoogtepunten van het programma worden de komende maanden bekendgemaakt.<\/p>\n
Agenda<\/h2>\n\n
\n\n\n\t| Time<\/th> | Subject<\/th> | Presenter<\/th>\n<\/tr>\n<\/thead>\n |
\n\n\t| 8:00 am<\/td> | Registration & light breakfast<\/td> | <\/td>\n<\/tr>\n |
\n\t| 8:30 am<\/td> | Welcome to Birmingham and the 11th Annual Erdheim-Chester Disease International Conference<\/td> | Gaurav Goyal<\/strong>
\nUniversity of Alabama at Birmingham, Birmingham, AL USA<\/td>\n<\/tr>\n\n\tKeynote Address<\/strong><\/td>\n<\/tr>\n\n\t| 8:45 am <\/td> | Diversity and Degeneration in
\nNeurohistiocytic Disease<\/td> | Nicole Coufal<\/strong>
\nUniversity of California, San Diego
\nUSA<\/td>\n<\/tr>\n\n\t| 9:25 am<\/td> | Break<\/td>\n<\/tr>\n | \n\tMorning Abstract Presentations Session 1: Cells, Clones & Circuits: Where Histiocytosis Begins (and Persists)<\/strong><\/td>\n<\/tr>\n\n\t| 9:35 am<\/td> | ARAF Mutations Drive Histiocytic Neoplasms
\nIn Vivo and Provide Insights into Cellular
\nOrigin<\/td> | Benjamin Durham<\/strong>
\nRutgers Cancer Institute, Robert
\nWood Johnson School of Medicine,
\nBrunswick, NJ<\/td>\n<\/tr>\n\n\t| 9:50 am<\/td> | Tracking BRAF V600E Persistence under MEK
\nInhibition in Histiocytoses: a B-cell\u2013enriched
\nsignal<\/td> | Julien Haroche<\/strong>
\nDepartment of Internal Medicine &
\nE3M Institute, Piti\u00e9-Salp\u00eatri\u00e8re
\nHospital, AP-HP \u2013 Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 10:05 am<\/td> | Distribution of MAP2K1 Variants Across
\nPeripheral Blood Cells in Erdheim-Chester
\nDisease and Other Histiocytoses<\/td> | Irena Ungureanu<\/strong>
\nAmbroise-Par\u00e9 Hospital, Pathology
\nDepartment, Boulogne-Billancourt,
\nFrance<\/td>\n<\/tr>\n\n\t| 10:20 am<\/td> | The Clonal Origin and Evolution of High-Risk
\nMultisystem Histiocytosis in Adults<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\t| 10:35 am<\/td> | Networking Break<\/td>\n<\/tr>\n | \n\tMorning Abstract Presentations Session 2: Genotype \u2192 Therapy: Biomarkers, Responses, and New Vulnerabilities<\/strong><\/td>\n<\/tr>\n\n\t| 10:50 am<\/td> | KRAS Mutations in Histiocytic Neoplasms:
\nMutation Spectrum and Response to MEK
\nInhibition<\/td> | Dongni Yi<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 11:05 am<\/td> | Cyclin D1 Overexpression Drives Replication
\nStress and Creates Therapeutic
\nVulnerabilities in Histiocytic Neoplasms<\/td> | Dongni Yi<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 11:20 am<\/td> | Clonal Hematopoiesis Predicts Response to
\nInterferon-\u03b1 in Erdheim-Chester Disease and
\nMyeloproliferative Neoplasms<\/td> | J\u00e9r\u00f4me Razanamahery<\/strong>
\nDijon University Hospital, France<\/td>\n<\/tr>\n\n\t| 11:35 am<\/td> | Impact of Additional Genetic Variants in the
\nCourse of Erdheim-Chester Disease\u2026 a
\nMulticentric Longitudinal Study of 445 French
\nPatients<\/td> | F\u00e9licien Triboulet<\/strong>
\nPiti\u00e9-Salp\u00eatri\u00e8re hospital, Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 11:50 am<\/td> | Group Photo<\/td> | <\/td>\n<\/tr>\n | \n\t| 12:00 pm<\/td> | Lunch<\/td>\n<\/tr>\n | \n\tAfternoon Abstract Presentations Session 3: Pixels to Patterns: ECD and Xanthogranuloma<\/strong><\/td>\n<\/tr>\n\n\t| 1:00 pm<\/td> | Central Nervous System Imaging
\nAbnormalities in Erdheim\u2013Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\t| 1:15 pm<\/td> | Musculoskeletal System Imaging
\nAbnormalities in Erdheim\u2013Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\t| 1:30 pm<\/td> | Patterns of Presentation and Outcomes in
\nAdult Xanthogranuloma<\/td> | Guneet Janda<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 1:45 pm<\/td> | Networking Break<\/td>\n<\/tr>\n | \n\tAfternoon Abstract Presentations Session 4: Care in the Real World: Treatment Patterns and Survivorship<\/strong><\/td>\n<\/tr>\n\n\t| 2:00 pm<\/td> | Real World Frontline Systemic Anti-Cancer
\nTreatment Patterns and Outcomes in
\nErdheim\u2013Chester Disease<\/td> | Carla Isabel Borre<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\t| 2:15 pm<\/td> | Burden of Chronic Health Conditions After
\nDiagnosis of Erdheim\u2013Chester Disease
\n(ECD): Early Results from the Histiocytic
\nDisorder Survivor Study<\/td> | Gaurav Goyal<\/strong>
\nUniversity of Alabama at
\nBirmingham, Birmingham, AL USA<\/td>\n<\/tr>\n\n\t| 2:30 pm<\/td> | Destombes-Rosai-Dorfman Disease:
\nClinical, Molecular Characteristics and
\nTreatment Response: data from a
\nretrospective cohort of 107 patients<\/td> | Julien Haroche<\/strong>
\nDepartment of Internal Medicine &
\nE3M Institute, Piti\u00e9-Salp\u00eatri\u00e8re
\nHospital, AP-HP \u2013 Sorbonne
\nUniversity, Paris, France<\/td>\n<\/tr>\n\n\t| 2:45 pm<\/td> | Considerations for Assessment and
\nTreatment of Neuropsychiatric Symptoms in
\nECD<\/td> | Anneka Johnston<\/strong>
\nRush University Medical Center,
\nChicago IL<\/td>\n<\/tr>\n\n\tPoster Presentations and Networking<\/strong><\/td>\n<\/tr>\n\n\t| 3:00 pm<\/td> | Erdheim-Chester Disease (ECD) is a Rare
\nHistiocytic Neoplasm of Non-Langerhans
\nCell Histiocytosis<\/td> | Abdalla Bowirrat<\/strong>
\nAriel University, Israel<\/td>\n<\/tr>\n\n\tDiagnostic challenges in mixed ErdheimChester Disease and Langerhans Cell
\nHistiocytosis in a 54-year-old male<\/td> | Sameer Andani<\/strong>
\nMofitt Cancer Center & University
\nof South Florida<\/td>\n<\/tr>\n\n\tA Mycosis Fungoides-like Drug Reaction
\nRapidly Resolving Following Switch from
\nBRAF Inhibitor to MEK Inhibitor Monotherapy
\nin Erdheim-Chester Disease<\/td> | Saipriya Ayyar<\/strong>
\nUniversity of Cincinnati\/UC Health,
\nCincinnati OH<\/td>\n<\/tr>\n\n\tMultimodality Imaging in Erdheim\u2013Chester
\nDisease: Radiologic Insights from Pediatric
\nand Adult Cases<\/td> | Priyanka Naranje<\/strong>
\nAll India Institute of Medical
\nSciences, New Delhi, India<\/td>\n<\/tr>\n\n\tCardiovascular System Imaging
\nAbnormalities in Erdheim-Chester Disease: A
\nSystematic Review<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\tBRAF-Positive Erdheim\u2013Chester Disease with
\nProgressive Pulmonary and Vascular
\nInvolvement Successfully Treated with
\nVemurafenib: A Case Report<\/td> | Hulya Yilmaz Tekinhatun<\/strong>
\nDiyarbakir Gazi Yasargil Training and
\nResearch Hospital, Turkey<\/td>\n<\/tr>\n\n\tConcurrent Erdheim-Chester Disease and
\nClassical Hodgkin Lymphoma with
\nunexpected response to lymphoma-directed
\ntherapy<\/td> | Rebecca Denson<\/strong>
\nNew York Presbyterian-Weill Cornell
\nMedicine, New York, NY<\/td>\n<\/tr>\n\n\tAbdominal Imaging Abnormalities in
\nErdheim-Chester Disease: A Systematic
\nReview<\/td> | Mustafa Abomohsen<\/strong>
\nBrookdale University Hospital and
\nMedical Center, Brooklyn, NY USA<\/td>\n<\/tr>\n\n\tPrevalence and distribution of ErdheimChester Disease in the UK estimated from
\nreferral to a National Advisory Panel<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\tChallenging Case Study<\/strong><\/td>\n<\/tr>\n\n\t| 3:45 pm<\/td> | All that glitters: retro-orbital
\nxanthogranuloma or ECD?<\/td> | Matthew Collin<\/strong>
\nNewcastle University, United
\nKingdom<\/td>\n<\/tr>\n\n\tChallenging Case Study<\/strong><\/td>\n<\/tr>\n\n\t| 4:15 pm<\/td> | The Clue Was the Blood Pressure: Atypical
\nErdheim\u2013Chester Disease<\/td> | Jithma Abeykoon<\/strong>
\nMayo Clinic, Rochester, MN USA<\/td>\n<\/tr>\n\n\tClosing Remarks & Student Abstract Award<\/strong><\/td>\n<\/tr>\n\n\t| 4:45 pm<\/td> | ECD Global Alliance into the Future<\/td> | Jerome Henson<\/strong>
\nExecutive Director, ECD Global
\nAlliance, DeRidder, LA USA<\/td>\n<\/tr>\n\n\t| 4:55 pm<\/td> | Junior Investigator \u2013 Best Student
\nPresentation Award<\/td> | Oshrat Hershkovitz-Rokah<\/strong>
\nAriel University & Assut<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\nDownload de agenda<\/a><\/span><\/p>\nRegistreer<\/a><\/span><\/p>\nLET OP:<\/strong> Registreer v\u00f3\u00f3r 1 februari om te profiteren van de vroegboekkorting! Bespaar $200 USD en registreer je voor slechts $300 USD! <\/p>\nMark Heaney Bewustzijnsprijs & prijs voor gemeenschapskampioen<\/h3>\n1 februari 2026 – Laatste dag om je nominatie in te dienen voor de Mark Heaney Awareness Award & Community Champion Award .<\/strong><\/p>\n | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download.png\")
<\/a><\/div>\n<\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-1.png\")
<\/a><\/div>\n<\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-2.png\")
<\/a><\/div>\n![\"\"](\"https:\/\/www.erdheim-chester.org\/wp-content\/uploads\/2026\/04\/download-3.png\")
<\/a><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"